As per the report, Biocon Biologics Limited, which focuses on biosimilars, is particularly exposed with about 40 per cent of ...

The global biosimilars market is set to witness a CAGR of ~15% in the next 5 years. Impending patent expiry of blockbuster ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

Shaw, Executive Chairperson of Biocon & Biocon Biologics, said the pharma industry faces long 'lab-to-market' timelines, high ...

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...

MUMBAI: If the government were to completely stop Russian crude imports by the state-owned oil companies, to avoid the 25% ...

Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure ...

Biocon's reported net profit for the quarter was ₹31 crore, compared to ₹660 crore in Q1FY25. Excluding one-time gains from a ...

Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit ...